Based on current operating plans, Erasca's cash, cash equivalents, and marketable securities, combined with net proceeds from the January 2026 offering, are expected to fund operations into the second half of 2028.
Bullish
Erasca focuses on RAS/MAPK pathway-driven cancers with promising clinical programs like ERAS-0015 and ERAS-4001, supported by a modality-agnostic pipeline and an experienced team.
Bearish
Erasca faces substantial operating losses and requires significant additional capital, while its unproven scientific approach and lengthy development process are challenged by intense competition and regulatory uncertainty.